Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
ORGANIZATION
Kichiro Matsumoto Elected as New Chief of Japan Medical Association
Kichiro Matsumoto, an executive board member of the Japan Medical Association (JMA), was elected as the new president of the powerful doctors’ lobby on June 25, replacing Toshio Nakagawa, who had previously dropped a bid for his second term. Dr…
To read the full story
Related Article
- Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
August 22, 2022
- Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
- JMA President Hopeful Matsumoto Vows to Boost Collaboration with Doctors, Govt; Matsubara Files for Election
May 25, 2022
- JMA Chief Nakagawa Drops Bid for Re-Election, Matsumoto Is Likely Winner
May 24, 2022
ORGANIZATION
- Medipal’s Choufuku Takes Over as JPWA Vice Chair
November 4, 2026
- Enhertu, Dupixent Win 2026 International Prix Galien Biotechnology Award
November 2, 2026
- Pharma Trade Groups Flag Potential Leak of 30,000 Email Addresses
November 2, 2026
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
- Pharma Labor Group Seeks Political Push for Price Hikes, Fair Cost Sharing
October 30, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…